B

Beam Therapeutics Tech Stack

CRISPR base-editing company scaling first therapeutic commercialization

Biotechnology Research Cambridge, Massachusetts 501–1,000 employees Founded 2017 Public Company

Beam is a public biotech firm advancing CRISPR base editing—a technique that edits single DNA/RNA bases without cutting strands—toward its first commercial product launch. The hiring acceleration (19 roles posted in 30 days) is concentrated in manufacturing, research, and data teams, with heavy director/senior-level hiring, signaling parallel ramps in GMP-scale production, clinical validation, and regulatory submissions. Active projects span commercial operations, treatment-center networks, and product-launch readiness, while pain points center on cGMP compliance, data-integrity gaps, and operational readiness—typical of a biotech transitioning from R&D to manufacturing and field deployment.

Tech Stack 12 technologies

Core StackSAS SAP AWS DeltaV MES OSI PI Veeva Quality SAS/GRAPH R Azure DigiCert SAML

What Beam Therapeutics Is Building

◆Challenges

Ensuring cgmp compliance
Data integrity gaps
High volume agreements
Compliance with 21 cfr part 11
First product commercialization
Operational readiness for launch
Treatment center qualification
Ensuring seamless patient access
Optimizing gene therapy delivery infrastructure
Site onboarding challenges

▲Active Projects

Data integrity gap assessment program
Prc/mlr review of promotional materials
Commercial operations readiness
Treatment center activation
Workflow & training development
Launch of risto-cel
Build strategic partnerships with treatment centers
Build world-class network
Product launch support
Continuous review of contracting playbooks

Hiring Activity

Accelerating25 roles · 20 in 30d

Department

Manufacturing

4

Research

4

Data

3

Engineering

3

Legal

3

Ops

3

Biometrics

2

Procurement

1

Seniority

Senior

14

Director

6

Mid

5

Manager

1

VP

1

Notable leadership hires: Director HEOR

Company intelligence

Find more companies like Beam Therapeutics by tech stack, pain points and active projects

Get started free

About Beam Therapeutics

Beam Therapeutics, founded in 2017 and publicly traded, develops precision genetic medicines using base editing to correct single-nucleotide disease drivers in DNA and RNA. The company targets serious genetic diseases across hematology and rare-disease indications. Operations span research, manufacturing, regulatory, and commercial functions across a 501–1,000-person workforce headquartered in Cambridge, Massachusetts. Current focus is on launch preparation for a lead therapeutic candidate, including treatment-center activation, workflow design, and contracting frameworks to support patient access and clinical delivery.

HeadquartersCambridge, Massachusetts

Company Size501–1,000 employees

Founded2017

Hiring MarketsUnited States

Frequently Asked Questions

What is Beam Therapeutics' primary technology platform?

CRISPR base editing—a genetic-medicine technique that makes permanent, targeted edits to single DNA and RNA bases without cutting the DNA strand, enabling precision correction of disease-driving mutations.

What are Beam Therapeutics' biggest operational challenges?

cGMP compliance, data-integrity gaps, high-volume contract management, 21 CFR Part 11 regulatory conformance, treatment-center qualification, and operational readiness for first-product launch.